Form 4: Incyte Executive Matteo Trotta Acquires Stock Options
SEC Form 4 Filing
EVP and GM of Dermatology US, Matteo Trotta, acquired stock options in Incyte Corp.
Summary
- Matteo Trotta, EVP and GM of Dermatology US at Incyte Corp, filed a Form 4 on January 22, 2025, reporting a transaction.
- On January 17, 2025, Trotta acquired 5,371 employee stock options with an exercise price of $71.93.
- These options become exercisable beginning January 17, 2025, in 37 installments, with 25% vesting on July 15, 2025, and the remainder vesting monthly over three years.
- Following the reported transaction, Trotta beneficially owns 5,371 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock option grants, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and are closely monitored by investors for insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 2024-08-02 | Date of Power of Attorney execution. |
| 2025-01-17 | Date of the stock option grant and start of the vesting period. |
| 2025-01-22 | Date of Form 4 filing. |
| 2025-07-15 | Date when the first 25% of the options vest. |
| 2035-01-16 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.